View in EDS

The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.

Saved in:
Bibliographic Details
Title: The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Authors: Peper-Gabriel JK; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Pavlidou M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Pattarini L; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Morales-Kastresana A; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Jaquin TJ; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Gallou C; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Hansbauer EM; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Richter M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Lelievre H; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France., Scholer-Dahirel A; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France., Bossenmaier B; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Sancerne C; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Riviere M; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Grandclaudon M; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Zettl M; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Bel Aiba RS; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Rothe C; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany., Blanc V; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France., Olwill SA; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3387-3399.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35121624
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Peper-Gabriel+JK%22">Peper-Gabriel JK</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Pavlidou+M%22">Pavlidou M</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Pattarini+L%22">Pattarini L</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Morales-Kastresana+A%22">Morales-Kastresana A</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Jaquin+TJ%22">Jaquin TJ</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Gallou+C%22">Gallou C</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Hansbauer+EM%22">Hansbauer EM</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Richter+M%22">Richter M</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Lelievre+H%22">Lelievre H</searchLink>; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Scholer-Dahirel+A%22">Scholer-Dahirel A</searchLink>; Institut de Recherches Internationales Servier Oncology R&D Unit, Suresnes, France.<br /><searchLink fieldCode="AU" term="%22Bossenmaier+B%22">Bossenmaier B</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Sancerne+C%22">Sancerne C</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Riviere+M%22">Riviere M</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Grandclaudon+M%22">Grandclaudon M</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Zettl+M%22">Zettl M</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Bel+Aiba+RS%22">Bel Aiba RS</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Rothe+C%22">Rothe C</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.<br /><searchLink fieldCode="AU" term="%22Blanc+V%22">Blanc V</searchLink>; Institut de Recherches Servier, Center for Therapeutic Innovation Oncology, Croissy-sur-Seine, France.<br /><searchLink fieldCode="AU" term="%22Olwill+SA%22">Olwill SA</searchLink>; Pieris Pharmaceuticals GmbH, Hallbergmoos, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3387-3399.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35121624
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-21-2762
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3387
    Titles:
      – TitleFull: The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Peper-Gabriel JK
      – PersonEntity:
          Name:
            NameFull: Pavlidou M
      – PersonEntity:
          Name:
            NameFull: Pattarini L
      – PersonEntity:
          Name:
            NameFull: Morales-Kastresana A
      – PersonEntity:
          Name:
            NameFull: Jaquin TJ
      – PersonEntity:
          Name:
            NameFull: Gallou C
      – PersonEntity:
          Name:
            NameFull: Hansbauer EM
      – PersonEntity:
          Name:
            NameFull: Richter M
      – PersonEntity:
          Name:
            NameFull: Lelievre H
      – PersonEntity:
          Name:
            NameFull: Scholer-Dahirel A
      – PersonEntity:
          Name:
            NameFull: Bossenmaier B
      – PersonEntity:
          Name:
            NameFull: Sancerne C
      – PersonEntity:
          Name:
            NameFull: Riviere M
      – PersonEntity:
          Name:
            NameFull: Grandclaudon M
      – PersonEntity:
          Name:
            NameFull: Zettl M
      – PersonEntity:
          Name:
            NameFull: Bel Aiba RS
      – PersonEntity:
          Name:
            NameFull: Rothe C
      – PersonEntity:
          Name:
            NameFull: Blanc V
      – PersonEntity:
          Name:
            NameFull: Olwill SA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 08
              Text: 2022 Aug 02
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1